A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Lurasidone (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Sumitomo Pharmaceuticals
- 10 Dec 2019 Primary endpoint (Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores) has been met.
- 10 Dec 2019 Results of non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia has published in the Psychiatry and Clinical Neurosciences
- 26 Dec 2018 Status changed from recruiting to completed.